These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15979704)

  • 21. Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies.
    Foss FM
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):58-63. PubMed ID: 10877054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epstein-barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia.
    Sohani AR; Ferry JA; Chang PS; Abramson JS
    J Clin Oncol; 2010 Feb; 28(5):e69-72. PubMed ID: 19917859
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical overview of pentostatin (Nipent) use in lymphoid malignancies.
    Dearden CE; Matutes E; Catovsky D
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):22-6. PubMed ID: 10877047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.
    Nabhan C; Gartenhaus RB; Tallman MS
    Leuk Res; 2004 May; 28(5):429-42. PubMed ID: 15068894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.
    Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Osterborg A; Mellstedt H
    Leukemia; 2004 Mar; 18(3):484-90. PubMed ID: 14749699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly.
    Alinari L; Geskin L; Grady T; Baiocchi RA; Bechtel MA; Porcu P
    Leuk Res; 2008 Aug; 32(8):1299-303. PubMed ID: 18096224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pentostatin treatment for a patient with chronic type adult T-cell leukemia undergoing hemodialysis].
    Arima N; Sugiyama T
    Rinsho Ketsueki; 2005 Nov; 46(11):1191-5. PubMed ID: 16440802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
    Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
    Elter T; Borchmann P; Schulz H; Reiser M; Trelle S; Schnell R; Jensen M; Staib P; Schinköthe T; Stützer H; Rech J; Gramatzki M; Aulitzky W; Hasan I; Josting A; Hallek M; Engert A
    J Clin Oncol; 2005 Oct; 23(28):7024-31. PubMed ID: 16145065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment with alemtuzumab in a case of refractory primary cutaneous CD30-negative CD8-positive cytotoxic large T-cell lymphoma.
    Gutierrez A; Rodriguez J; Ramos R; Gines J; Sampol A; Galmes B; Besalduch J
    Eur J Haematol; 2004 May; 72(5):377-8. PubMed ID: 15059077
    [No Abstract]   [Full Text] [Related]  

  • 31. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma.
    Katsuya H; Yamanaka T; Ishitsuka K; Utsunomiya A; Sasaki H; Hanada S; Eto T; Moriuchi Y; Saburi Y; Miyahara M; Sueoka E; Uike N; Yoshida S; Yamashita K; Tsukasaki K; Suzushima H; Ohno Y; Matsuoka H; Jo T; Suzumiya J; Tamura K
    J Clin Oncol; 2012 May; 30(14):1635-40. PubMed ID: 22473153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Current concepts in chronic lymphocytic leukemia. Better chances for young patients].
    Hallek M; Bergmann M; Goede V; Fingerle-Rowson G; Schweighofer C; Schmitt B; Wendtner CM; Emmerich B
    MMW Fortschr Med; 2003 Jul; 145(27-28):46-9. PubMed ID: 14587189
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL).
    Ceesay MM; Matutes E; Taylor GP; Fields P; Cavenagh J; Simpson S; Ho A; Devereux S; Mufti GJ; Pagliuca A
    Leuk Res; 2012 Jul; 36(7):857-61. PubMed ID: 22209076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.
    Lin TS; Flinn IW; Lucas MS; Porcu P; Sickler J; Moran ME; Lucas DM; Heerema NA; Grever MR; Byrd JC
    Leukemia; 2005 Jul; 19(7):1207-10. PubMed ID: 15858611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T-cell prolymphocytic leukemia.
    Dearden CE
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S239-43. PubMed ID: 19778847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
    Montillo M; Tedeschi A; Miqueleiz S; Veronese S; Cairoli R; Intropido L; Ricci F; Colosimo A; Scarpati B; Montagna M; Nichelatti M; Regazzi M; Morra E
    J Clin Oncol; 2006 May; 24(15):2337-42. PubMed ID: 16618945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.
    Demko S; Summers J; Keegan P; Pazdur R
    Oncologist; 2008 Feb; 13(2):167-74. PubMed ID: 18305062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antibody therapy in hematology and oncology - part 1].
    Kneba M; Schrader C; Köhne H
    Med Klin (Munich); 2008 Dec; 103(12):843-59. PubMed ID: 19099214
    [No Abstract]   [Full Text] [Related]  

  • 40. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
    Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
    J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.